NASDAQ:GOVX

GeoVax Labs Q1 2026 Earnings Results & Report

GeoVax Labs logo
$2.02 +0.32 (+18.48%)
Closing price 11/16/2026 04:00 PM Eastern
Extended Trading
$1.92 -0.10 (-4.70%)
As of 11/16/2026 07:58 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

GeoVax Labs beat analyst earnings expectations in its Q1 2026 results, released May 14, 2026. The company reported EPS of -$62.88 versus the -$92.2111 consensus estimate.

Earnings Announcement Details

Quarter
Q1 2026
Report Date
Time
After Market Closes
Conference Call
7:00 AM ET

GeoVax Labs EPS Results

Actual EPS
-$62.88
Consensus EPS
-$92.2111
Beat/Miss
Beat by +$29.3311
One Year Ago EPS
N/A

GeoVax Labs Revenue Results

Actual Revenue
N/A
Expected Revenue
N/A
Beat/Miss
N/A
YoY Revenue Growth
N/A

GeoVax Labs Q1 2026 Earnings FAQ

GeoVax Labs (NASDAQ:GOVX) reported earnings of -$62.88 per share for Q1 2026, beating the consensus estimate of -$92.2111. The report was announced on Thursday, May 14, 2026.

GeoVax Labs Earnings Headlines

GeoVax Labs (GOVX) Expected to Post Earnings on Thursday
Pentagon magnet restrictions take effect January 1, 2027
A NASDAQ-listed company has signed a term sheet outlining a potential 75-year agreement with the U.S. Army. It would build and operate a rare earth processing facility on an active military base, with the Army receiving first right to production. The timing matters. New Pentagon restrictions on certain Chinese-origin rare earth magnets take effect January 1, 2027, while China controls more than 90% of global rare earth processing. The company's mine-to-magnet platform spans feedstock agreements, processing facilities, metallization technology, and downstream manufacturing, with initial commercial output targeted for 2027.tc pixel
GeoVax Enters Into $1 Million Revolving Loan Agreement
GeoVax Enters Into $1 Million Revolving Loan Agreement
See More GeoVax Labs Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like GeoVax Labs? Sign up for Earnings360's daily newsletter to receive timely earnings updates on GeoVax Labs and other key companies, straight to your email.

About GeoVax Labs

GeoVax Labs (NASDAQ:GOVX) is a clinical-stage biotechnology company developing vaccines and immunotherapies for infectious diseases and cancer. The company’s research is based in part on modified vaccinia Ankara (MVA), a viral-vector platform designed to prompt immune responses, including through the presentation of virus-like particles.

Its vaccine pipeline includes GEO-CM04S1, an investigational COVID-19 vaccine being studied in clinical trials, as well as programs targeting other infectious diseases. GeoVax also develops Gedeptin, an investigational cancer therapy designed to make tumor cells more susceptible to treatment.

GeoVax is based in the United States and focuses on research and clinical development; its candidates are investigational and have not been established here as approved products.

View GeoVax Labs Profile